INS and type 2 diabetes mellitus: After a twofold progressive increase in total insulin daily dose on CSII, HbA1c dropped by −1.7 % and the benefit was maintained during a 7-year period of follow-up, indicating durability of CSII efficacy in the treatment of T2D.13 A third observational study from 31 French hospitals has reported results after a 2-year follow-up of 100 obese T2D patients previously treated by an intensified MDI regimen and switched to CSII.